Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 201–300 of 1,000
Reza, N., Gruen, J., & Bozkurt, B. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100093 · Cited by 84
“…demonstrated a more favorable treatment effect in women in a prespecified subgroup analysis (rate ratio, 0.73 [95% CI, 0.59 – 0.90] in women; 1.03 [95% CI, 0.84 – 1.25] in men; p interaction = 0.017) with the predominant attributable benefit due to a greater reduction in HF hospitalization [44,45].”
BackgroundInfluentialGenetic architecture of heart failure with preserved versus reduced ejection fraction
Joseph, J., Liu, C., Hui, Q., Aragam, K. G., Wang, Z., CHAREST, B. R., Huffman, J. E., Keaton, J. M., Edwards, T. L., Demissie, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35323-0 · Cited by 86
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 87
Docherty, K. F., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Mueller, K., Viswanathan, P., Scalise, A. V., Lam, C. S. P., Senni, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072011 · Cited by 85
Self-citationEmpagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.010 · Cited by 81
Immune regulation of cardiac fibrosis post myocardial infarction
Zaidi, Y., Aguilar, E. G., Troncoso, M., Ilatovskaya, D. V., & DeLeon‐Pennell, K. Y. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109837 · Cited by 92
Association of Left Ventricular Ejection Fraction with Mortality and Hospitalizations
Angaran, P., Dorian, P., Ha, A. C. T., Thavendiranathan, P., Tsang, W., Leong-Poi, H. M., Woo, A., Dias, B. F., Wang, X., Austin, P. C., et al. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.12.016 · Cited by 83
McGuire, D. K., Zinman, B., Inzucchi, S. E., Wanner, C., FITCHETT, D. H., Anker, S. D., Pocock, S., Kaspers, S., George, J. T., von Eynatten, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30344-2 · Cited by 82
Solomon, S. D., Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., Jhund, P. S., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3266 · Cited by 79
Self-citationRole of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease
Frąk, W., Dąbek, B., Balcerczyk-Lis, M., Motor, J., Radzioch, E., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Antioxidants · doi:10.3390/antiox13060687 · Cited by 86
“These findings underscore the importance of sacubitril/valsartan as a promising therapeutic option for patients with heart failure and concomitant CKD, offering both cardiovascular and renal benefits [116,119,120].”
BackgroundZile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
Self-citationThe cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74
Self-citationHeart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic
Verwerft, J., Soens, L., Wynants, J., Meysman, M., Jogani, S., Plein, D., Stroobants, S., Herbots, L., & Verbrugge, F. H. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad141 · Cited by 75
Pellicori, P., Ferreira, J. P., Mariottoni, B., Rocca, H. B., Ahmed, F. Z., Verdonschot, J. A. J., Collier, T. J., Cuthbert, J. J., Petutschnigg, J., Mujaj, B., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1716 · Cited by 75
Self-citationGlobal Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
Tromp, J., Claggett, B. L., Liu, J., Jackson, A. M., Jhund, P. S., Køber, L., Widimsky, J., Jr., Boytsov, S. A., Chopra, V., Anand, I. S., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007901 · Cited by 72
Self-citationJudge, D. P., Alexander, K. M., Cappelli, F., Fontana, M., García‐Pavía, P., Gibbs, S. D., Grogan, M. A., Hanna, M. A., Masri, A., Maurer, M. S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.042 · Cited by 77
Redefining Heart Failure With a Reduced Ejection Fraction
Butler, J., Anker, S. D., & Packer, M. (2019) · JAMA · doi:10.1001/jama.2019.15600 · Cited by 71
Self-citationGatti, M., Antonazzo, I. C., Diemberger, I., De Ponti, F., & Raschi, E. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915663 · Cited by 68
Kammerlander, A. A., Donà, C., Nitsche, C., Koschutnik, M., Schönbauer, R., Duca, F., Zotter‐Tufaro, C., Binder, C., Aschauer, S., Beitzke, D., et al. (2020) · Radiology · doi:10.1148/radiol.2020200195 · Cited by 74
Jhund, P. S., Ponikowski, P., Docherty, K. F., Gasparyan, S. B., Böhm, M., Chiang, C.-E., Desai, A. S., Howlett, J., Kitakaze, M., Petrie, M. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053659 · Cited by 64
Self-citationBuono, M. G. D., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R. A., Crea, F., et al. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.011 · Cited by 73
Branca, L., Sbolli, M., Metra, M., & Fudim, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12586 · Cited by 73
The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies
Cai, Z., Wu, C., Xu, Y., Cai, J., Zhao, M., & Zu, L. (2022) · Aging and Disease · doi:10.14336/ad.2022.0523 · Cited by 76
“Over a median follow-up of 35 months, the participants randomized to receive sacubitril/valsartan therapy failed to show a marked improvement in the primary composite outcome of cardiovascular death and hospitalization for HF compared with those who received treatment with valsartan only [110].”
BackgroundInciardi, R. M., Abanda, M. H., Shah, A. M., Čikeš, M., Claggett, B. L., Skali, H., Vaduganathan, M., Prasad, N., Litwin, S. E., Merkely, B. P., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.010 · Cited by 69
Self-citationBrann, A. M., Miller, J. E., Eshraghian, E. A., Park, J. J., & Greenberg, B. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2947 · Cited by 71
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 76
Microvascular Disease and Small-Vessel Disease: The Nexus of Multiple Diseases of Women
Patel, H. N., Aggarwal, N. T., Rao, A., Bryant, E., Sanghani, R. M., Byrnes, M., Kalra, D. K., Dairaghi, L., Braun, L. T., Gabriel, S. E., et al. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.7826 · Cited by 70
Recent successes in heart failure treatment
Lam, C. S. P., Docherty, K. F., Ho, J. E., McMurray, J. J. V., Myhre, P. L., & Omland, T. (2023) · Nature Medicine · doi:10.1038/s41591-023-02567-2 · Cited by 71
“The PARAGON-HF trial compared sacubitril/valsartan with vals-artan in patients with a LVEF ≥ 45% 25 .”
MethodSelf-citationPacker, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1646 · Cited by 62
Self-citationSavarese, G., Settergren, C., Schrage, B., Thorvaldsen, T., Löfman, I. H., Sartipy, U., Mellbin, L., Meyers, A., FARSANI, S. F. F., Brueckmann, M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.04.068 · Cited by 76
Current and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 72
Martin, N., Manoharan, K., Davies, C., & Lumbers, R. T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721.pub3 · Cited by 85
Similarities and Differences Between HFmrEF and HFpEF
Li, P., Zhao, H., Zhang, J., Ning, Y., Tu, Y., Xu, D., & Zeng, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678614 · Cited by 75
Clinical practice guideline for the management of hypertension in China
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 68
Heart Failure with Preserved Ejection Fraction—a Concise Review
Adamczak, D., Oduah, M.-T. A., Kiebalo, T., Nartowicz, S., Bęben, M., Pochylski, M., Ciepłucha, A., Gwizdała, A., Lesiak, M., & Straburzyńska‐Migaj, E. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01349-3 · Cited by 68
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2018 · Cited by 73
“Similarly, HFpEF has been variably defined as LVEF > 40-55% (10,12,17-21).”
BackgroundSelf-citationSacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
Niu, C., Yang, S., Ou, S., Wu, C., Huang, P., Hung, C., Lin, C., & Li, S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026407 · Cited by 70
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Self-citationHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“158,165 Likewise, the nonsteroidal MRA finerenone may be considered for patients with HFpEF, T2D, and CKD (see Section 2.3.5.”
InfluentialDAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Kaplinsky, E. (2020) · Drugs in Context · doi:10.7573/dic.2019-11-3 · Cited by 68
Rosselló, X., & González‐Del‐Hoyo, M. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.06.027 · Cited by 65
Selvaraj, S., Claggett, B. L., Pfeffer, M. A., Desai, A. S., Causland, F. R. M., McGrath, M. M., Anand, I. S., van Veldhuisen, D. J., Køber, L., Janssens, S. P., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1984 · Cited by 70
Self-citationPocock, S., Ferreira, J. P., Packer, M., Zannad, F. M., Filippatos, G. S., Kondo, T., McMurray, J. J. V., Solomon, S. D., Januzzi, J. L., Iwata, T., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2607 · Cited by 63
Self-citationAlcaide-Aldeano, A., Garay, A., Alcoberro, L., Jiménez‐Marrero, S., Yun, S., Tajes, M., García‐Romero, E., Díez‐López, C., González‐Costello, J., Mateus-Porta, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041199 · Cited by 64
“In fact, medical therapies that have given good results in improving prognosis in patients with HFrEF, such as ACE inhibitors, beta blockers, or sacubitril/valsartan, have not elucidated conclusive results in those with HFpEF so far [9].”
BackgroundMethodLiang, M., Bian, B., & Yang, Q. (2022) · Clinical Cardiology · doi:10.1002/clc.23754 · Cited by 62
“The PARAGON‐HF trial, including 4822 patients with HFpEF of LVEF ≥ 45%, demonstrated that sacubitril‐valsartan, a drug currently used to replace ACEI/ARB in the treatment of HFrEF, did not significantly lower the rate of total hospitalizations for HF, and death from cardiovascular causes compared with valsartan and su…”
MethodMancini, G. B. J., O’Meara, E., Zieroth, S., Bernier, M., Cheng, A. Y. Y., Cherney, D. Z. I., Connelly, K. A., Ezekowitz, J., Goldenberg, R. M., Leiter, L. A., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.04.029 · Cited by 56
Ledwidge, M. T., Dodd, J. D., Ryan, F., Sweeney, C. M., McDonald, K., Fox, R., Shorten, E., Zhou, S., Watson, C. J., Gallagher, J., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0065 · Cited by 64
Management of patients with heart failure and preserved ejection fraction
Piadlo, A., & Campbell, P. C. (2023) · Heart · doi:10.1136/heartjnl-2022-321097 · Cited by 72
McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Self-citationObesity-Related Heart Failure with Preserved Ejection Fraction
Harada, T., & Obokata, M. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.02.004 · Cited by 65
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 72
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
ZHANG, S.-Y. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.03.002 · Cited by 70
Lam, C. S. P., Voors, A. A., Piotr, P., McMurray, J. J. V., & Solomon, S. D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa158 · Cited by 59
Self-citationLejeune, S., Roy, C., Slimani, A., Pasquet, A., Vancraeynest, D., Vanoverschelde, J., Gerber, B. L., Beauloye, C., & Pouleur, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01242-5 · Cited by 62
“Indeed most recent clinical trial using sacubitril-valsartan in HFpEF had disappointing results [2], although it could decrease the rate of hospitalisation in specific subgroups [3].”
BackgroundCausland, F. R. M., Lefkowitz, M. P., Claggett, B. L., Packer, M., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Rouleau, J. L., Shi, V. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2421 · Cited by 60
Self-citationGenetic, Molecular, and Cellular Determinants of Sex-Specific Cardiovascular Traits
Vaura, F. C., Palmu, J., Aittokallio, J., Kauko, A., & Niiranen, T. (2022) · Circulation Research · doi:10.1161/circresaha.121.319891 · Cited by 60
Kintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 62
“In TOPCAT, PARAGON-HF, and EMPEROR-Preserved even more than 90%, and in FIDELIO-DKD and FIGARO-DKD more the 95% of the included patients suffered from arterial hypertension underscoring the importance of high blood pressure in the pathophysiology of HFpEF [6, 7, 15, 16, 18].”
BackgroundPharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
Zafeiropoulos, S., Farmakis, I. T., Milioglou, I., Doundoulakis, I., Gorodeski, E. Z., Konstantinides, S., Cooper, L. B., Zanos, S. P., Stavrakis, S., Giamouzis, G., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.014 · Cited by 63
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 68
Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients
Kaye, D. M., Nanayakkara, S., Wang, B., Shihata, W., Marques, F. Z., Esler, M., Lambert, G. W., & Mariani, J. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.11.007 · Cited by 59
“For example, despite evidence for marked efficacy in HFrEF, neprilysin inhibition has been shown to benefit only a subset HFpEF patients with left ventricular ejection fraction (LVEF) at the lower range of normal.(3,4) Recently, sodium-glucose transport protein 2 inhibitors were shown to exert favorable effects in HFp…”
BackgroundPatel, R., Sharma, A., Prasad, A., & Bansal, S. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100705 · Cited by 66
Stoicescu, L., Crișan, D., Morgovan, C., Avram, L., & Ghibu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020794 · Cited by 65
Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations
Vancheri, F., Longo, G., & Henein, M. Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1340708 · Cited by 67
Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 66
“In PARAGON-HF, sacubi-tril/valsartan showed a 50% risk reduction in composite kidney events (HR 0.50 [95%CI: 0.33–0.77]), though with no difference in the risk for progression to ESRD [37].”
BackgroundInfluentialNeuen, B. L., Vaduganathan, M., Claggett, B. L., Beldhuis, I. E., Myhre, P. L., Desai, A. S., Skali, H., Causland, F. R. M., McGrath, M. M., Anand, I. S., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.009 · Cited by 57
Self-citationSacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Mann, D. L., Greene, S. J., Givertz, M. M., Vader, J. M., Starling, R. C., Ambrosy, A. P., Shah, P. M., McNulty, S. E., Mahr, C., Gupta, D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.005 · Cited by 57
Self-citationSex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Ueda, K., Fukuma, N., Adachi, Y., Numata, G., Tokiwa, H., Toyoda, M., Otani, A., Hashimoto, M., Liu, P., & Takimoto, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738218 · Cited by 61
Cai, A., Qiu, W., Zhou, Y., Feng, Y., Chen, J., Xia, S., Li, W., Liao, Y., Li, X., Zhou, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2654 · Cited by 60
Self-citationAtrial Fibrillation in Heart Failure With Preserved Ejection Fraction
Cikes, M., Planinc, I., Claggett, B., Cunningham, J., Milicic, D., Sweitzer, N., Senni, M., Gori, M., Linssen, G., Shah, S. J., et al. (2022) · JACC: Heart Failure · doi:10.1016/j.jchf.2022.01.018 · Cited by 49
Self-citationCurrent Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
Budde, H., Hassoun, R., Mügge, A., Kov́acs, Á., & Hamdani, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.928232 · Cited by 62
“, 2014) and sacubitril/valsartan (Solomon et al., 2012; Solomon et al., 2019) showed neutral outcomes in large clinical trials on HFpEF patients.”
BackgroundOstrominski, J. W., Claggett, B. L., Miao, Z. M., Causland, F. R. M., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.005 · Cited by 56
Self-citationRenal Denervation to Treat Heart Failure
Sharp, T. E., & Lefer, D. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093431 · Cited by 59
“The PARAGON-HF trial (NCT01920711) (79) enrolled 4,822 patients randomized to a combination of valsartan-only therapy.”
BackgroundMethodRosalia, L., Öztürk, Ç., Shoar, S., Fan, Y., Malone, G., Cheema, F. H., Conway, C., Byrne, R. A., Duffy, G. P., Malone, A. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.06.002 · Cited by 59
“In addition, compared with the valsartan-only cohort, absolute risk reduction in the dual-agent group was found to be more pronounced in patients enrolled early (#30 days) after hospitalization than in patients who enrolled later or who were never hospitalized (47,70).”
BackgroundYamamoto, K. I., & Rakugi, H. (2021) · Hypertension Research · doi:10.1038/s41440-021-00706-1 · Cited by 63
“A total of 4822 HF patients with NYHA class 3–4, EF of 45% or higher, elevated levels of natriuretic peptides, and structural heart disease were randomly assigned to receive S/V 200 mg twice daily or valsartan 160 mg twice daily [56].”
BackgroundMethodNADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
Teuber, J. P., Essandoh, K., Hummel, S. L., Madamanchi, N. R., & Brody, M. J. (2022) · Antioxidants · doi:10.3390/antiox11091822 · Cited by 56
Recurrent Events in Cardiovascular Trials
Gregson, J., Stone, G. W., Bhatt, D. L., Packer, M., Anker, S. D., Zeller, C., Redfors, B., & Pocock, S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.024 · Cited by 60
Self-citationRosselló, X., Ferreira, J. P., Pocock, S., McMurray, J. J. V., Solomon, S. D., Lam, C. S. P., Girerd, N., Pitt, B., Rossignol, P., & Zannad, F. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1740 · Cited by 56
Self-citationCyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
Petraina, A., Nogales, C., Krahn, T., Mucke, H. A., Lüscher, T. F., Fischmeister, R., Kass, D. A., Burnett, J. C. J., Hobbs, A. J., & Schmidt, H. H. H. W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab240 · Cited by 58
Kondo, T., Dewan, P., Anand, I. S., Desai, A. S., Packer, M., Zile, M. R., Pfeffer, M. A., Solomon, S. D., Abraham, W. T., Shah, S. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063642 · Cited by 54
Self-citationCastrichini, M., Manca, P., Nuzzi, V., Barbati, G., Luca, A. D., Korcova, R., Stolfo, D., Lenarda, A. D., Merlo, M., & Sinagra, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040906 · Cited by 59
Ambrosy, A. P., Parikh, R., Sung, S. H., Narayanan, A., Masson, R., Lam, P.-Q., Kheder, K., Iwahashi, A., Hardwick, A. B., Fitzpatrick, J. K., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.35152 · Cited by 59
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0011 · Cited by 58
Lahoz, R., Proudfoot, C., Fonseca, A. F., Loefroth, E., Corda, S., Jackson, J., Cotton, S. E., & Studer, R. L. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s297816 · Cited by 55
Bayés‐Genís, A., Aimo, A., Jhund, P. S., Richards, M., de Boer, R. A., Arfsten, H., Fabiani, I., Lupón, J., Anker, S. D., González, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2675 · Cited by 58
Self-citationAnker, S. D., Butler, J., Usman, M., Filippatos, G. S., Ferreira, J. P., Bocchi, E. A., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02041-5 · Cited by 53
Self-citationEndocrine functions of the heart: from bench to bedside
Volpe, M., Gallo, G., & Rubattu, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac759 · Cited by 51
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
Litwin, S. E., Komtebedde, J., Hu, M., Burkhoff, D., Hasenfuss, G. P., Borlaug, B. A., Solomon, S. D., Zile, M. R., Mohan, R. C., Khawash, R., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.030 · Cited by 53
Self-citationObesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 56
“173 At this regard, in the PARALLAX study, SAC/VAL compared with standard renin – angiotensin system inhibitor treatment or placebo resulted in a signi fi cant decrease in plasma NT-proBNP levels at 12 weeks, but did not signi fi cantly improve 6 min walking distance at 24 weeks.”
MethodKresoja, K., Rommel, K., Wachter, R., Henger, S., Besler, C., Klöting, N., Schnelle, M., Hoffmann, A., Buttner, P. G., Ceglarek, U., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2291 · Cited by 52
Inzucchi, S. E., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00308-4 · Cited by 57
Self-citationEscobar, C., Palacios, B., Varela, L. F., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175199 · Cited by 56
“≥60%), as some clinical trials have suggested a different efficacy of some drugs according to EF [17,38].”
BackgroundGorica, E., Geiger, M. A., Venanzio, L. D., Atzemian, N., Kleeberger, J., Grigorian, D., Mongelli, A., Veseli, B. E., Mohammed, S. A., Ruschitzka, F. T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02774-w · Cited by 55
Savira, F., Wang, B. H., Kompa, A. R., Ademi, Z., Owen, A. J., Zoungas, S., Tonkin, A. M., Liew, D., & Zomer, E. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320938272 · Cited by 53
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
Sutanto, H., Dobrev, D., & Heijman, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168994 · Cited by 52
“In PARAGON-HF, sacubitril/valsartan did not significantly lower cardiovascular mortality and hospitalization risk in the overall population [26], although a post-hoc stratification by sex revealed that sacubitril/valsartan may significantly improve clinical endpoints in women with HFpEF [27].”
BackgroundSuna, S., Hikoso, S., Yamada, T., Uematsu, M., Yasumura, Y., Nakagawa, A., Takeda, T., Kojima, T., Kida, H., Oeun, B., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038294 · Cited by 51
Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis
Smolgovsky, S. A., Theall, B. P., Wagner, N., & Alcaide, P. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00545.2023 · Cited by 52
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
von Haehling, S., Aßmus, B., Bekfani, T., Dworatzek, E., Edelmann, F., Hashemi, D., Hellenkamp, K., Kempf, T., Raake, P., Schütt, K. A., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02396-4 · Cited by 54
Female Heart Health: Is GPER the Missing Link?
Groban, L., Tran, Q., Ferrario, C. M., Sun, X., Cheng, C. P., Kitzman, D. W., Wang, H., & Lindsey, S. H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00919 · Cited by 52
“This is greatly needed given the disappointing results of the recent PARAGON trial (178), and the other 7 large randomized trials of HFpEF that failed to achieve their pre-determined primary endpoint (179).”
ResultThuijs, D. J. F. M., Milojevic, M., Stone, G. W., Puskas, J. D., Serruys, P. W. J. C., Sabik, J. F., Dressler, O., Crowley, A., Head, S. J., & Kappetein, A. P. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1681 · Cited by 49
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
Greenberg, B. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0002 · Cited by 55
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.